Barinthus Biotherapeutics plc (BRNS) — Financial Flexibility Index

Latest as of September 2025: -0.44x

Barinthus Biotherapeutics plc (BRNS) has a Financial Flexibility Index of -0.44x as of September 2025. Free cash flow of $-10.73 Million (operating CF $-10.73 Million minus capex $0.00) represents 0% of total liabilities ($24.64 Million). Check BRNS cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Financial Flexibility Index

-0.44x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-10.73 Million
Operating CF − Capex

Total Liabilities

$24.64 Million
USD

Capital Expenditures

$0.00
USD

Barinthus Biotherapeutics plc Financial Flexibility Index (2019–2024)

Historical Financial Flexibility Index trend for Barinthus Biotherapeutics plc across 6 annual periods. For the full cash flow conversion analysis, see how efficiently does Barinthus Biotherapeutics plc generate cash.

Annual Financial Flexibility Index for Barinthus Biotherapeutics plc (2019–2024)

Year-by-year free cash flow to debt coverage for Barinthus Biotherapeutics plc. Explore Barinthus Biotherapeutics plc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2024 -0.93x $-28.05 Million $-28.94 Million $30.19 Million ▲ +43.8%
2023 -1.65x $-45.51 Million $-50.92 Million $27.51 Million ▼ -438.7%
2022 -0.31x $-8.29 Million $-14.43 Million $27.00 Million ▲ +72.5%
2021 -1.12x $-31.44 Million $-32.58 Million $28.15 Million ▼ -459.8%
2020 -0.20x $-10.73 Million $-11.03 Million $53.81 Million ▲ +56.0%
2019 -0.45x $-18.63 Million $-18.76 Million $41.12 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities